Search This Blog

Saturday, April 6, 2019

Pin-sized sensor could bring chemical ID to smartphone-sized devices

Imagine pointing your smartphone at a salty snack you found at the back of your pantry and immediately knowing if its ingredients had turned rancid.
Devices called spectrometers can detect dangerous chemicals based on a unique “fingerprint” of absorbed and emitted light. But these light-splitting instruments have long been both bulky and expensive, preventing their use outside the lab.
Until now. Engineers at the University of Wisconsin-Madison have developed a  that is so small and simple that it could integrate with the camera of a typical cell phone without sacrificing accuracy.
“This is a compact, single-shot spectrometer that offers  with low fabrication costs,” says Zhu Wang, who was among the team of electrical engineers that created the device.
The researchers published a description of the devices March 4, 2019, in the journal Nature Communications.
The team’s devices also have an advanced capability called hyperspectral imaging, which collects information about each individual pixel in an image order to identify materials or detect specific objects amidst a complicated background. Hyperspectral sensing, for example, could be used to detect seams of valuable minerals within rock faces or to identify specific plants in a highly vegetated area.
Every element’s spectral fingerprint includes unique emitted or absorbed —and the spectrometer’s ability to sense that light is what has enabled researchers to do everything from analyze the composition of unknown compounds to reveal the makeup of distant stars.
Spectrometers usually rely on prisms or gratings to split light emitted from an object into discrete bands—each corresponding to a different . A camera’s photodetector can capture and analyze those bands; for example, the spectral fingerprint of the element sodium consists of two bands with wavelengths of 589 and 590 nanometers.
Human eyes see 590-nanometer wavelength light as a yellowish-orange shade. Shorter wavelengths correspond to blues and purples, whereas longer wavelengths appear red. Sunlight contains a complete rainbow mixed together, which we see as white.
To resolve the difference among a mixture of different colors, spectrometers usually must be relatively large with a long path length for light beams to travel and separate.
Yet the team created tiny , measuring just 200 micrometers on each side (roughly one-20th the area of a ballpoint pen tip) and delicate enough to lie directly on a sensor from a typical digital camera.
That small size was possible because the researchers based their device on specially designed materials that forced incoming light to bounce back and forth several times before reaching the sensor. Those internal reflections elongated the path along which  traveled without adding bulk, boosting the devices’ resolution.
And the devices performed , resolving two distinct images (of the numbers five and nine) from a snapshot of an overlaid projection that combined the pair into something indistinguishable to the naked eye.
Now the team hopes to boost the ‘s spectral resolution as well as the clarity and crispness of the images it captures. Those improvements could pave the way for even more enhanced sensors.

Explore further

More information: Zhu Wang et al. Single-shot on-chip spectral sensors based on photonic crystal slabs, Nature Communications (2019). DOI: 10.1038/s41467-019-08994-5

Investors should not buy into craze for hemp stocks, Barron’s says

Congress legalized hemp and its soothing extract cannabidiol, or CBD, and now the stock market cannot get enough of the stuff, Bill Alpert writes in this week’s edition of Barron’s. Cannabis producers like Canopy Growth (CGC), Aurora Cannabis (ACB) and Tilray (TLRY) quickly got into hemp and the stocks of companies that have long bet their business on CBD have doubled in recent months, including Charlotte’s Web (CWBHF) and GW Pharmaceuticals (GWPH), he notes. Unfortunately, there are no bargains among hemp or marijuana stocks these days, the author contends

E. coli outbreak affecting 5 states

U.S. health officials say they are investigating an outbreak of E. coli gastrointestinal illness that’s already affected 72 people across five Eastern states.
The origin of the foodborne illnesses remains unknown, the U.S. Centers for Disease Control and Prevention said late Friday.
“The investigation is still ongoing and a specific food item, grocery store, or restaurant chain has not been identified as the source of infections,” the CDC said in a statement. States affected are Georgia, Kentucky, Ohio, Tennessee and Virginia.
Cases of illness first began to be reported March 2, and the last reported case occurred March 29. Although no deaths have been reported, “of 47 people with information available, eight have been hospitalized” because their cases have been so severe, the CDC said.
This outbreak has been linked to the E. coli O103 strain of bacterium, and the CDC says people typically get sick within three to five days of eating E. coli-contaminated food.
“Most people get diarrhea (often bloody), severe stomach cramps and vomiting,” the agency said. “Most people recover within a week, but some illnesses can last longer and be more severe.”
There are ways you can protect yourself, however. Be sure to wash hands while preparing food, and cook meats thoroughly.
“To kill harmful germs, cook beef steaks and roasts to an internal temperature of at least 145 degrees Fahrenheit and allow to rest for three minutes after you remove meat from the grill or stove,” the CDC advises. “Cook ground beef and pork to a minimum  of 160 degrees Fahrenheit.”
Also, “wash hands, counters, cutting boards, and utensils after they touch raw meat,” the agency said.

Explore further

More information: There’s more on E. coli at foodsafety.gov.

NIOSH Seeks Firefighters for Data on Cancer Risk

Learning more about firefighters’ increased risk for certain cancers is the aim of a voluntary registry being created by the U.S. National Institute for Occupational Safety and Health (NIOSH).
It’s seeking more than 1.1 million firefighters to participate in the National Firefighter Registry.
“Firefighters put their lives on the line to ensure our safety in emergencies, but their jobs may also put them at risk for long-term health effects such as cancer,” Dr. John Howard, director of NIOSH, said in an agency news release.
Firefighters have higher odds for digestive, lung, throat and urinary cancers.
The registry will also highlight advances to safeguard firefighters, including improvements in the design and care of personal protective equipment, as well as practices to reduce exposure to hazardous substances.
“We look forward to receiving this formal input from our partners in the fire service on how we can make sure they are engaged in this process as we move forward. Their contributions will be important to the overall success of this registry,” said Kenny Fent, head of the National Firefighter Registry program.
Enrollment is expected to begin in 2020. The registry is especially seeking minorities and women, who have not been well-represented in past research.
A NIOSH study launched in 2010 included more than 30,000 career firefighters serving between 1950 and 2010, the largest study ever of U.S. firefighters.
It examined not only deaths from cancer, but also diagnoses of certain kinds of cancer, including testicular and prostate cancers, which have higher survival rates. It also looked at other causes of death to better understand firefighters’ risk compared to the general public.
Results of that study led to a call for a national registry with a focus on understudied groups of firefighters, according to NIOSH.
More information
The U.S. National Institute for Occupational Safety and Health has more on firefighters.

FDA Approves Supersaturated-Oxygen Device After Stenting in Heart Attack

A system that allows intracoronary delivery of blood “supersaturated” with oxygen after coronary stenting has received market approval from the US Food and Drug Administration (FDA), the developer, Therox, announced today.
The SuperSaturated Oxygen (SSO₂) therapy system, indicated for use immediately after stenting for acute ST-segment elevation myocardial infarction (STEMI) in the left-anterior-descending (LAD) coronary artery, aims to limit the extent of acute myocardial ischemia and therefore final infarct size.
The system combines oxygen-supersaturated saline with autologous blood, which is delivered over 60 minutes starting immediately after stenting opens the artery. “The superoxygenated blood helps reduce capillary swelling to restore blood flow to surrounding tissue and decrease infarct size,” according to the company.
The FDA approval marks 10 years since an FDA advisory committeerecommended against the system’s approval, in part to await further safety and efficacy data after clinical end-point concerns in the AMIHOT 2 study, which had been presented in 2007.
A combined analysis of that trial and the preceding AMIHOT trial, as previously reported here, suggested a significant reduction in infarct size by Tc-99m sestamibi single-photon-emission computed tomography (SPECT) 2 weeks after the procedure using SSO₂, compared with a control group, in the patients with large anterior STEMI.
But in AMIHOT 2, there was also a trend toward more major adverse cardiac events (MACE) in the group that received the supersaturated blood treatment.
More recently, the 2018 Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction (IC-HOT) study provided more safety data. It suggested the SSO₂ therapy was safe in 100 patients with STEMI and left-main coronary culprit arteries, finding no elevated risk for a primary end point of death, reinfarction, clinically driven target-vessel revascularization, stent thrombosis, severe heart failure, or TIMI major or minor bleeding.

Judge orders hearings on objections to already-consummated CVS-Aetna merge

A federal judge on Friday said he wants to hear in court from witnesses who object to the Justice Department’s decision last year to approve CVS Health Corp.’s nearly $70 billion acquisition of Aetna Inc.—a highly unusual move that threatens to shake up the already-consummated deal.
U.S. District Judge Richard Leon in Washington, D.C., is reviewing a department settlement last fall that allowed the merger after the companies agreed to sell off assets related to Medicare drug coverage.
“This is a matter of great consequence to a lot of people,” Judge Leon said during a brief court hearing. Health care “is a high priority issue for tens of millions of families,” he added. The judge, a George W. Bush appointee, last December said he was concerned the department hadn’t adequately addressed broader potential competitive harms raised by the merger.
At the time, he didn’t halt CVS’s CVS, +1.24%   integration of the Aetna assets but made clear he wanted to spend additional time considering the settlement. CVS had volunteered to Judge Leon that it would keep parts of its Aetna operations separate until he did so.
A federal law called the Tunney Act requires the government to have proposed merger settlements approved by a federal court, which determines whether the deal is in the public interest.

UT Health San Antonio Plans New Accelerator for Faculty Research

The University of Texas Health Science Center at San Antonio is starting an internal accelerator program for inventors who work at the institution, with the goal of picking a first group of five to eight prospective entrepreneurs around May.
The accelerator, which UT Health is calling TechNovum, will run its first program from June through October and will conclude with two days of presentations for the researchers to pitch the products they’ve developed. The program will include training on market validation, developing a business plan, and mentoring on making a pitch to investors, among other training.
TechNovum is going to be operated as a part of UT Health’s office of technology commercialization, which will take applications from inventors whose products have already gone through the office’s standard validation process. When a UT Health faculty member alerts the office of an invention that has potential to be commercialized, the office runs the product through 12 weeks of analysis—both product and market validation called a technology management report—to help the inventor and university determine if they might want to license the invention or maybe develop a startup out of it.
Inventors who get a favorable report will be eligible for the accelerator, said John Gebhard, the assistant vice president for the commercialization office. John Fritz and Sean Thompson, who both work out of the commercialization office with a focus on bringing inventions to market, will be co-directors of the accelerator. The program is an effort to formalize business, marketing, and entrepreneurial training that the office previously did on an ad-hoc basis, Fritz said during an interview yesterday at the university.
“Doing this is more efficient than what we’ve had to do, which was more one-on-one, individual mentoring,” Fritz said.
Because most of the inventions are so early stage, the accelerator may focus on different subjects than other accelerators for more advanced companies, such as Houston’s TMCx for health IT and medical devices, Techstars on the tech side of the startup world, or incubators like JLabs. San Antonio has other accelerator and startup programs, including a couple run by VelocityTX, which operates a “pre-accelerator” and another accelerator for international companies considering a move to the US, neither of which are solely focused on life sciences.
TechNovum will use a curriculum developed by business coach Wendy Kennedy (VelocityTX uses the same curriculum), which aims to help potential entrepreneurs figure out things like market fit and competitive edge. Fritz said the TechNovum will offer additional mentorship on issues specific to UT Health researchers who are developing products related to life sciences, such as manufacturing and quality control, regulatory matters, reimbursement, and partnering a product.
UT Health also plans to bring in outside mentors from the business community to talk to the group of researchers whose products are picked for the accelerator. Thompson, the other co-director, said the accelerator is an effort to make practical use out of research done by faculty at the university.
“There’s some people who might get bothered about this focus on commercialization,” Thompson said during the interview at the commercialization office. “Basic research is absolutely necessary, but research by itself, alone, has never saved anyone’s life. It’s the use of what you learn from that basic research and the application of that that is really most important.”